Daily Stock Analysis, ILMN, Illumina Inc, priceseries

Illumina Inc. Daily Stock Analysis
Stock Information
Open
292.34
Close
292.47
High
295.26
Low
291.86
Previous Close
293.52
Daily Price Gain
-1.05
YTD High
314.75
YTD High Date
Jan 18, 2019
YTD Low
268.62
YTD Low Date
Jan 30, 2019
YTD Price Change
-2.05
YTD Gain
-0.70%
52 Week High
372.61
52 Week High Date
Sep 28, 2018
52 Week Low
221.49
52 Week Low Date
Mar 2, 2018
52 Week Price Change
63.34
52 Week Gain
27.64%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Jan 3. 2017
131.13
Jan 30. 2017
157.03
18 Trading Days
19.75%
Link
LONG
Dec 28. 2017
217.52
Jan 29. 2018
238.83
20 Trading Days
9.80%
Link
LONG
Mar 5. 2018
230.88
Mar 21. 2018
248.53
12 Trading Days
7.64%
Link
LONG
May 4. 2018
244.82
May 25. 2018
264.95
15 Trading Days
8.22%
Link
LONG
Jul 6. 2018
286.13
Jul 27. 2018
305.01
15 Trading Days
6.60%
Link
Company Information
Stock Symbol
ILMN
Exchange
NasdaqGS
Company URL
http://www.illumina.com
Company Phone
8582024500
CEO
Francis A. deSouza
Headquarters
California
Business Address
5200 ILLUMINA WAY, SAN DIEGO, CA 92122
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001110803
About

Illumina, Inc. develops, manufactures and markets integrated systems for the analysis of genetic variation and function. The company provides sequencing and array-based solutions for genetic analysis in addition to selling products, it provide genotyping, NIPT and whole-genome sequencing services. Its customers include leading genomic research centers, academic institutions, government laboratories, hospitals, and reference laboratories as well as pharmaceutical, biotechnology, agrigenomics, commercial molecular diagnostic, and consumer genomics companies. The company was founded by David R. Walt, John R. Stuelpnagel, Anthony W. Czarnik, Lawrence A. Bock and Mark S. Chee in April 1998 and is headquartered in San Diego, CA.

Description

Illumina, Inc. provides sequencing and array-based solutions for genetic analysis. The company's sequencing by synthesis technology provides researchers with various applications and the ability to sequence mammalian genomes. It also offers arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as allow for the detection of known genetic markers on a single array. In addition, the company provides various library preparation and sequencing kits to simplify workflows and accelerate analysis; and genome sequencing, genotyping, and non-invasive prenatal testing services. It serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, agrigenomics, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as through life-science distributors. It has collaboration agreements with IBM Watson Health to access genome data interpretation by integrating Watson for genomics into Illumina's BaseSpace Sequence Hub and tumor sequencing process; and NRGene to develop new molecular breeding tools for cattle to support global food production. The company also has a co-development agreement with Munich Leukemia Laboratory GmbH and IBM Watson Health to build a cognitive technology prototype to help researchers improve leukemia treatment. Illumina, Inc. was founded in 1998 and is headquartered in San Diego, California.